Nykode Therapeutics (NYKD) PEGS EUROPE 2024 presentation summary

Technology platform and approach

• APC-targeted immunotherapy platform enables tailored immune responses for oncology and autoimmune diseases.

• Modular vaccine design includes targeting, dimerization, antigenic, and modulatory units for flexibility.

• Vaccines can be delivered as DNA, mRNA, viral vectors, or recombinant proteins.

• Targeting specific APC receptors allows induction of either immune activation or tolerance.

Pipeline and partnerships

• Broad pipeline spans early to late-stage oncology, infectious disease, and autoimmune programs.

• Lead asset VB10.16 targets high unmet needs in cervical and head & neck cancers.

• Strategic collaborations with Genentech and Regeneron valued at over $1.64 billion plus royalties.

• Genentech holds exclusive rights to VB10.NEO, an individualized neoantigen cancer vaccine.

• Regeneron partnership covers multiple oncology and infectious disease programs.

Financial position

• Cash position of $136.5 million as of June 30, 2024, supporting ongoing R&D and partnerships.